An independent two-stage DCF analysis by a frontier AI model.
Boston Scientific is executing at a very high level. By shifting its portfolio toward higher-growth, higher-margin categories like structural heart (WATCHMAN) and electrophysiology (FARAPULSE), the company has successfully accelerated its revenue growth well past its large-cap peers. The strategy of tuck-in acquisitions to augment internal R&D is paying off, creating a deeply entrenched portfolio of complex devices that surgeons rely upon daily. This creates immense recurring revenue and high switching costs.
However, the market has fully recognized this outperformance. At a current price near $70, the stock trades at a premium multiple (P/E ~36x) that leaves little room for execution missteps. While the underlying business is phenomenal and generating substantial free cash flow, our DCF model suggests that the current valuation fully prices in the next several years of double-digit growth. We view the stock as slightly overvalued at these levels, though it remains a premier hold for long-term investors seeking high-quality healthcare exposure.
An 11.0% free cash flow growth rate reflects the company's strong top-line momentum (nearly 16% recent sales growth) driven by high-margin electrophysiology and structural heart products, balanced against ongoing R&D and acquisition integration costs.
An 8.0% discount rate is utilized. As a large-cap, diversified medical device manufacturer with highly predictable revenue streams tied to non-discretionary medical procedures, BSX boasts a relatively low risk profile and cost of capital.
A 3.0% terminal growth rate assumes Boston Scientific will continue to grow slightly faster than overall GDP, buoyed by the long-term demographic tailwinds of an aging global population requiring more cardiovascular interventions.
Intrinsic value per share under varying discount rate and terminal growth rate assumptions.
| WACC ↓ / Terminal → | 2.0% | 2.5% | 3.0% | 3.5% | 4.0% |
|---|---|---|---|---|---|
| 2.0% | $69.31 | $55.45 | $46.21 | $39.61 | $34.66 |
| 2.5% | $79.21 | $61.61 | $50.41 | $42.65 | $36.97 |
| 3.0% | $92.42 | $69.31 | $55.45 | $46.21 | $39.61 |
| 3.5% | $110.90 | $79.21 | $61.61 | $50.41 | $42.65 |
| 4.0% | $138.63 | $92.42 | $69.31 | $55.45 | $46.21 |
■ Undervalued vs current price ■ Overvalued vs current price
An 11% rate models aggressive but achievable growth. BSX's recent top-line growth is exceptional for a large-cap medtech company, and its newer product lines carry very high gross margins, which should drive strong compounding free cash flow over the next five years.
It can be, provided the company sustains double-digit growth. The market is willing to pay a premium for Boston Scientific because its revenue streams are highly visible, insulated from macroeconomic shocks (medical procedures are generally non-discretionary), and protected by high barriers to entry.
The primary risks are multiple contraction if growth slows, unexpected delays in FDA approvals for new pipeline devices, or aggressive pricing pushback from consolidated hospital networks looking to cut costs.
Disclaimer: The numbers presented on this page are for educational and entertainment purposes only. They are the result of a deterministic mathematical model fed with assumptions generated by an Artificial Intelligence (Gemini 3.1). This does not constitute investment advice. Always conduct your own due diligence before investing in the stock market.